XORTX Announces Share Consolidation
Rhea-AI Summary
XORTX (NASDAQ: XRTX) approved a one-for-five share consolidation effective March 27, 2026, reducing issued and outstanding common shares from 6,962,218 to approximately 1,392,444, subject to rounding. The action is intended to satisfy Nasdaq’s $1.00 continual listing requirement and a 10-day price condition by April 13, 2026.
No name change will occur. Fractional post-consolidation shares will be cancelled if under one-half or rounded up if one-half or greater; no cash will be paid for fractions. Convertible securities will be proportionately adjusted. Trading will resume under XRTX with new CUSIP 98420Q405.
Positive
- Issued shares reduced from 6,962,218 to ~1,392,444
- Maintains Nasdaq listing by targeting $1.00 price requirement
- Trading to continue on Nasdaq and TSXV under XRTX with new CUSIP
Negative
- No cash paid for fractional shares; fractions cancelled if <0.5
- Outstanding convertible securities will be proportionately adjusted
Key Figures
Market Reality Check
Peers on Argus
Current data flag this as stock-specific. Scanner shows QNRX down ~6.9% and ONCO up ~5.6%, while XRTX’s pre-news move was -0.78%, indicating mixed peer action rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 18 | Board/financing update | Positive | +6.5% | New director nominees tied to a significant financing arrangement. |
| Mar 05 | Meeting materials filed | Neutral | +7.8% | Mailing of meeting documents including proposed share consolidation. |
| Feb 04 | Acquisition timeline update | Positive | -17.7% | Extended deadline to close renal anti-fibrotic program acquisition. |
| Dec 31 | Research & corporate update | Positive | +1.4% | New gout genetic pathway research and confirmation of US$1.1M financing. |
| Oct 29 | Registered direct offering | Negative | +2.9% | US$1.1M registered direct offering and related warrants issuance. |
Recent corporate and financing-related announcements often saw positive price reactions, while some pipeline/acquisition updates drew negative responses.
Over the last several months, XORTX has focused on shareholder approvals and financing flexibility, including meeting materials and a vote on a consolidation of up to five pre-consolidation for one post-consolidation share on March 24, 2026. Governance and financing steps (new director nominees tied to a significant financing and the meeting documentation) drew gains of 6.45% and 7.78%. By contrast, an update on the renal anti-fibrotic acquisition on February 4, 2026 saw a -17.71% move. The current consolidation implementation follows directly from this earlier meeting and 6-K disclosures.
Market Pulse Summary
This announcement finalizes a 1-for-5 share consolidation, cutting outstanding shares from 6,962,218 to about 1,392,444 to address Nasdaq’s $1.00 minimum bid requirement ahead of an April 13, 2026 deadline. It follows prior 6-K disclosures and shareholder approval. Before the news, XRTX traded at $0.382, below its 0.68 200-day MA and far from its $1.41 52-week high, highlighting broader financing and listing risks that remain relevant to monitor.
Key Terms
convertible securities financial
nasdaq capital market regulatory
tsx venture exchange regulatory
cusip technical
AI-generated analysis. Not financial advice.
CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company’s board of directors has approved consolidating (the “Consolidation”) its common shares (“Shares”) on the basis of one post-consolidation Share for every five pre-consolidation Shares, effective March 27, 2025 (the “Effective Date”). The Company will not undergo a name change in connection with the Consolidation.
The Consolidation has been approved by the TSX Venture Exchange (the “TSXV”) and follows approval of a consolidation of the Shares on the basis of a range of up to five pre-consolidation Shares for every one post-consolidation Share at the annual and special meeting of shareholders of the Company held on March 24, 2026. As a result of the Consolidation, the number of issued and outstanding Shares will be reduced from 6,962,218 to approximately 1,392,444, subject to adjustment for rounding. No fractional shares will be issued in connection with the Consolidation. In the event a holder of Common Shares would be entitled to fractional Common Shares as the result of the Consolidation, the fractional Common Shares shall be either: (i) cancelled, if less than one-half (1/2) of a full Common Share, or (ii) rounded up to the nearest whole number, if greater than or equal to one-half (1/2) of a full Common Share. No cash consideration will be paid in respect of fractional shares. The exercise or conversion price and/or the number of Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
The reason for the consolidation is to maintain compliance with (i) NASDAQ’s continual listing requirements (namely, that the Company’s shares trade above
The Shares will continue to trade on the TSXV and the Nasdaq Capital Market (“Nasdaq”) under the symbol “XRTX” on a post-Consolidation basis, under a new CUSIP number – 98420Q405. The Shares are expected to begin trading on a post-consolidation basis on the TSXV and Nasdaq when markets open on or about Friday, March 27, 2026.
Shareholders of record as of the Effective Date will receive a letter of transmittal from TSX Trust Company, the transfer agent for the Shares, providing instructions for the exchange of their Shares as soon as practicable following the Effective Date. Until surrendered, each share certificate representing pre-Consolidation Shares will represent the number of whole post-Consolidation shares to which the holder is entitled as a result of the Consolidation.
About XORTX Therapeutics Inc.
XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.
For more information, please contact:
| Allen Davidoff, CEO | Nick Rigopulos, Director of Communications |
| adavidoff@xortx.com | nick@alpineequityadv.com |
| +1 403 455 7727 | +1 617 901 0785 |
Forward Looking Statements
This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.
FAQ
What is the XRTX share consolidation ratio and effective date?
How many XRTX shares will be outstanding after the consolidation?
Why did XRTX consolidate shares and what Nasdaq condition must it meet?
Will XRTX shareholders receive cash for fractional shares after the consolidation?
Will XRTX shares keep the same ticker and what is the new CUSIP?
How will convertible securities be affected by the XRTX consolidation?
